Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal function during angiostatic therapy with rofecoxib + pioglitazone + trofosfamide or capecitabine
DRKS00000119Phase 2Completed
- Sponsor
- Abteilung für Hämatologie und Internistische Onkologie, Klinikum der Universität Regensburg
- Start
- Jun 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rofecoxib, pioglitazone, trofosfamide and capecitabine in cancer (2 arms), sponsored by Abteilung für Hämatologie und Internistische Onkologie, Klinikum der Universität Regensburg. Primary endpoint: Renal function during angiostatic therapy. Started Jun 2009; status: completed.
02
Drugs
rofecoxibpioglitazonetrofosfamidecapecitabine
03
Conditions
cancer
Beyond the preview
Go deeper on DRKS00000119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000119.